Bio-Techne Corp (TECH)

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. It operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. Its Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.

Ticker
TECH
Exchange
Nasdaq
Sector
Healthcare
Industry
Biotechnology
Market cap
$11.41B
52-week range
$43.20 - $72.88

Valuation

Share price
$72.75 (close of Nov 18, 2026)
P/E (TTM)
66.03x
Price to book
5.27x
Price to free cash flow
37.01x
Enterprise value
$11.34B
Book value per share
$13.79

Price performance

PeriodChange
1 day+0.17%
5 days-0.07%
1 month+0.25%
3 months+0.73%
6 months+63.74%
Year to date+23.70%
1 year+25.11%
3 years+19.16%
5 years-41.23%
10 years+177.78%
All time+66,414.29%

Short interest

As of
Oct 30, 2026
Short % of float
4.93%
Shares short
7.70M
Days to cover
2.73
Change since prior report
+2.00%
Source
FINRA consolidated short interest

Members of Congress who disclosed TECH trades

April McClain Delaney · Robert Bresnahan · Julie Johnson

Super investors holding TECH

Ruane Cunniff (Ruane, Cunniff & Goldfarb L.P.) · Lee Ainslie (Maverick Capital LTD) · Mairs & Power (Mairs & Power Inc) · Henry Ellenbogen (Durable Capital Partners LP) · Wallace Weitz (Weitz Investment Management) · Ken Griffin (Citadel)

Profitability and growth

Return on equity
8.63%
Return on invested capital
8.05%
Return on assets
7.03%
Return on capital employed
10.40%
Gross margin
65.77%
Net margin
14.97%
EBITDA margin
28.74%
Revenue growth
-0.38%
Net income growth
147.77%
Free cash flow growth
2.60%

Cash flow and balance sheet

Free cash flow yield (TTM)
2.70%
Current ratio
2.28x
Net debt to EBITDA
-0.19x

Latest reported year

Period end
Jun 30, 2026
Fiscal year
2026
Revenue
$1.22B
Cost of revenue
$415.97M
Gross profit
$799.07M
EBITDA
$349.25M
Net income
$181.86M
Earnings per share
$1.17
Research and development
$94.77M
Interest expense
$9.63M
Shares outstanding
155.96M

Income statement by year

Period endRevenueGross profitNet incomeEPS
2026-06-30$1.22B$799.07M$181.86M$1.17
2025-06-30$1.22B$790.27M$73.40M$0.47
2024-06-30$1.16B$769.73M$168.10M$1.07
2023-06-30$1.14B$769.82M$285.26M$1.81
2022-06-30$1.11B$756.50M$272.05M$1.73
2021-06-30$931.03M$632.85M$140.41M$0.91
2020-06-30$738.69M$483.19M$229.30M$1.50
2019-06-30$714.01M$473.49M$96.07M$0.64
2018-06-30$642.99M$432.14M$126.15M$0.84
2017-06-30$563.00M$374.54M$76.09M$0.51

Margins and returns by year

Period endGross marginNet marginReturn on equityReturn on capital
2026-06-3065.77%14.97%8.63%8.05%
2025-06-3064.80%6.02%3.83%3.27%
2024-06-3066.41%14.50%8.13%7.60%
2023-06-3067.72%25.10%14.51%10.15%
2022-06-3068.42%24.61%15.99%12.74%
2021-06-3067.97%15.08%8.94%11.48%
2020-06-3065.41%31.04%16.60%6.07%
2019-06-3066.31%13.46%8.24%7.83%
2018-06-3067.21%19.62%11.69%9.60%
2017-06-3066.53%13.51%8.01%6.55%

Cash and debt by year

Period endCashDebt
2026-06-30$264.71M$200.00M
2025-06-30$162.19M$346.00M
2024-06-30$152.86M$319.00M
2023-06-30$204.31M$350.00M
2022-06-30$247.03M$243.41M
2021-06-30$231.55M$328.83M
2020-06-30$270.89M$344.24M
2019-06-30$166.03M$492.66M
2018-06-30$181.75M$339.00M
2017-06-30$157.71M$343.77M

Free cash flow by year

Period endFree cash flowStock-based compensation
2026-06-30$263.22M$41.37M
2025-06-30$256.55M$40.83M
2024-06-30$236.10M$38.04M
2023-06-30$216.15M$39.23M
2022-06-30$280.36M$42.18M
2021-06-30$307.86M$48.98M
2020-06-30$153.47M$32.37M
2019-06-30$156.21M$32.28M
2018-06-30$149.43M$28.24M
2017-06-30$128.54M$14.63M

Dividend history

Most recent payment
Nov 13, 2026
Paid in the last twelve months
$0.32
Payment dateDividend per share
2026-11-13$0.08
2026-08-24$0.08
2026-05-18$0.08
2026-02-13$0.08
2025-11-17$0.08
2025-08-18$0.08
2025-05-19$0.08
2025-02-14$0.08

Investor relations

Past earnings dates

ReportedFiscal periodEPS estimate
2026-11-06Sep 2026$0.40
2026-08-12Jun 2026$0.46
2026-05-06Mar 2026$0.48
2026-02-04Dec 2025$0.34
2025-11-05Sep 2025$0.36
2025-08-06Jun 2025$0.46
2025-05-07Mar 2025$0.45
2025-02-05Dec 2024$0.33

Filings and sources

Company website
bio-techne.com
SEC filings
10-K, 10-Q and 8-K on EDGAR
Earnings calendar
All upcoming reports

Similar companies

Insmed Inc (INSM) · Incyte Corp (INCY) · Moderna, Inc. (MRNA) · Regeneron Pharmaceuticals, Inc. (REGN) · Vertex Pharmaceuticals Inc (VRTX) · Eli Lilly & Co (LLY) · Johnson & Johnson (JNJ) · AbbVie Inc. (ABBV)

All Healthcare companies

Understanding these figures

Price-to-earnings ratio · Short interest · Discounted cash flow · Free cash flow · Earnings per share · Return on equity · Gross margin vs net margin · Reading a balance sheet · Debt and leverage · Dividend yield · Insider transactions and Form 4 · How to read a stock chart

Explore

Company directory · S&P 500 heatmap · Earnings calendar · Super investor holdings · Congress trades